Yiming and Hexaell’s HepaCure Biocolumn Receives IND Approval for HBV-Induced Liver Failure
China-based Yiming (Beijing) Cell Biotechnology Co., Ltd (also known as Ubrigene) and its partner Shanghai...
November 2022
Yiming and Vitalgen’s Gene Therapy VGR-R01 Receives CDE Approval for Bietti Crystalline Dystrophy
China-based Yiming (Beijing) Cell Biotechnology Co., Ltd (also known as Ubrigene) and its partner Shanghai...
LianBio’s TP-03 Begins Phase III Trial for Demodectic Blepharitis in China
Shanghai-based biopharmaceutical company LianBio (OTCMKTS: LIANY) has announced the first patient dosing in a Phase...
Ascletis Files IND Application for COVID-19 Oral Inhibitor ASC11 with FDA
China-based Ascletis Pharma Inc. (HKG: 1672) has announced that the Investigational New Drug (IND) application...
RemeGen’s Telitacicept Shows Positive Results in Phase II Myasthenia Gravis Study
China-based RemeGen Co., Ltd (HKG: 9995, SHA: 688331) has released data from a Phase II...
Immunochina Pharmaceuticals Raises Funds for Gene Therapy Development
Beijing-based gene therapy specialist Immunochina Pharmaceuticals has reportedly raised “hundreds of millions” of renminbi in...
BGI Genomics Receives NMPA Approval for Chromosome Aneuploidy Detection Kit
China-based genomics firm BGI Genomics Co., Ltd (SHE: 300676), the Shenzhen-listed subsidiary of BGI Group,...
NMPA Suspends GSK’s Avodart Amid Inspection Findings
The National Medical Products Administration (NMPA) has decided to suspend the import, sales, and use...
Antengene’s ATG-017 Gets FDA Approval for Phase I Clinical Study
Antengene Corporation has announced receiving approval from the US Food and Drug Administration (FDA) to...
China Grand’s STC3141 Reaches Primary Endpoint in ARDS Phase Ib Study
China-based Grand Pharmaceutical Group Limited (HKG: 0512) has announced that the Phase Ib clinical study...
Allogene Overland Biopharm Completes State-of-the-Art AlloCAR T Facility in Shanghai
Allogene Overland Biopharm, a joint venture between Overland Pharmaceuticals and Allogene Therapeutics, Inc. (NASDAQ: ALLO),...
Shandong Buchang Partners with REMD Bio for Bispecific Antibody Development
China-based Shandong Buchang Pharmaceuticals Co., Ltd (SHA: 603858) has announced a co-development and licensing agreement...
Eucure Biopharma Partners with ISU ABXIS to Develop Tri-Specific Antibodies Using YH003
Eucure Biopharma, a wholly-owned subsidiary of Sino-US contract research organization (CRO) Biocytogen, has entered into...
Zhejiang Medicine’s ARX788 Advances to Phase II Study for HER2-Positive Cholangiocarcinoma
China-based Zhejiang Medicine Co., Ltd (SHA: 600216) has received approval from the National Medical Products...
Simcere’s SIM0235 Begins US Phase I Trial for Anti-Tumor Therapy
China-based Simcere Pharmaceutical Group (HKG: 2096) has announced the enrollment of the first patient in...